Kleinfeld, Kaplan & Becker is one of the most distinguished and experienced law firms in the country specializing in FDA law.
Our practice concentrates on the regulation of products subject to the jurisdiction of the U.S.
Food and Drug Administration (FDA) — including food, drugs, biologics, cosmetics, medical devices, dietary supplements, controlled substances, tobacco products, and animal food and drugs — as well as related areas of advertising law. We also advise on regulatory issues affecting similar products (such as meat and poultry regulated by the United States Department of Agriculture (USDA); and consumer products regulated by the Consumer Products Safety Commission (CPSC)).
Our firm has a comprehensive administrative law practice, including the submission of petitions and comments relating to rulemaking and the resolution of administrative actions before the FDA, Federal Trade Commission (FTC), Environmental Protection Agency (EPA), USDA, Drug Enforcement Administration (DEA) and other Federal and state agencies. We conduct litigation, primarily in Federal court, and our attorneys are admitted to practice before a number of Federal courts as well as in the District of Columbia and various States. We also practice before the National Advertising Division (the advertising self-regulatory program of BBB National Programs, Inc.) and engage in alternative dispute resolution and settlement negotiations on behalf of clients.
Our clients consist principally of manufacturers, importers, distributors, and retailers of FDA-regulated products, including major multinational corporations as well as mid-sized companies and smaller start-up ventures. We also work closely with healthcare institutions, other law firms, private equity firms, and other specialists in our areas of concentration.
History
Our firm was founded by Vincent A. Kleinfeld, one of the first private practitioners of food and drug law. Mr. Kleinfeld entered government service in 1935 and eventually became Head of the General Regulations Unit, Criminal Division, in the U.S. Department of Justice, where he was in charge of litigation under the Federal Food, Drug, and Cosmetic Act. From 1950-1951, he served as chief counsel for the House Select Committee to Investigate the Use of Chemicals in Food Products (the “Delaney Committee”).
In 1953, Mr. Kleinfeld became a partner in the Washington, DC law firm of Bernstein, Kleinfeld & Alper, where he advised numerous clients in the pharmaceutical, food and cosmetics industries. He was joined by Alan H. Kaplan, who had been a Food Law Institute fellow in 1956-1957 and an attorney in FDA’s Office of the Chief Counsel. In 1967, they created the firm of Kleinfeld & Kaplan. The firm adopted its current name when Robert H. Becker, who was counsel to Norwich Eaton Pharmaceuticals, became a partner in the early 1970s.







Accolades
KKB has been consistently recognized as one of the finest law firms in the field; for example, we have been ranked among the Best Law Firms of 2010 – 2024 for FDA Law and Advertising Law by U.S. News & World Report and Best Lawyers®.
Suzan Onel Leads as Editor, KKB Attorneys Author Chapters in PLI Medical Device Law and Regulation Answer Book (Tenth Edition)
We are pleased to announce the release of the newly updated edition of the Practicing
Nine KKB Attorneys Recognized in 2027 editions of The Best Lawyers in America® and Best Lawyers: Ones to Watch® in America
Kleinfeld, Kaplan and Becker LLP (KKB) is proud to announce that 9 attorneys from our
Four KKB Attorneys Author Chapters in 2025 Edition of FDLI’s Top Food and Drug Cases
Kleinfeld, Kaplan, & Becker is proud to announce that four KKB attorneys authored chapters in
Suzan Onel, Stacy Ehrlich Named 2026 Super Lawyers
We are pleased to announce that KKB partners, Suzan Onel and Stacy Ehrlich, were selected to this year’s
Allulose and Sugar-Free Claims: The Seventh Circuit’s Reversal in Franco v. Chobani and FDA’s Amicus Intervention
The U.S. Food and Drug Administration rarely appears as amicus curiae in private consumer class
HHS Advances Two Food Policy Reforms: A Mandatory GRAS Notification Proposed Rule and a Forthcoming Federal Definition of Ultra-Processed Foods
On August 10, 2026, the U.S. Department of Health and Human Services (HHS) announced two
SNAP Food Restriction Waivers in 2026: What Retailers Should Know
Over the past year, several states have applied and received approval from the United States
FDA Adopts New Enforcement Discretion Policy for “No Artificial Colors” Claims for Foods Intended for Human Consumption
Today, the Food and Drug Administration (FDA) signaled a significant shift in its policies with